Fundraising Fox
Thrombolex
Kingston, US · Founded 2016 · Delaware corporation · 2 known investors
Find your way into Thrombolex
Sign up to see every warm intro you have to Thrombolex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Thrombolex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.
Founders & leadership
Thrombolex was founded in 2016 by Riyaz Bashir.
RB
Riyaz BashirInnovator / Creator of BASHIR Endovascular Catheters
JC
John CerminaroChief Financial OfficerJohn Cerminaro is an executive with over 25 years of experience in financial markets, financial management, operations, and technology. He has held roles involving financial management strategy and firm operations in the financial services sector.
MW
Marvin WoodallNamed on SEC filing
BG
Brian G. FirthNamed on SEC filing
TR
Todd RichmondNamed on SEC filing
Board
DB
KH
Keegan HarperBoard director
PA
Paul A. StewartBoard director
CD
Investors · 2
Delaware Crossing Investor Grouplisted by Delaware Crossing Investor GroupPhiladelphia
How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75Mvia David Bonita · board
How we know: OrbiMed's portfolio page · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$55.6M disclosed across 6 of 7 rounds · 2017–2026
▶$32.8MraisedMar 2026 · 22 investors · Other Health CareRule 506(b)
▶$32.8MraisedMar 2026 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David BonitaDirector
- Keegan HarperDirector
- Paul A. StewartDirector
- Sam LiangDirector
- Marvin WoodallExecutive Officer, Director
- John CerminaroExecutive Officer
- Clay DeMarcusDirector
- Michael J. CerminaroExecutive Officer, Director
- Offering amount
- $51.1M
- Amount sold
- $32.8M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedJun 2024 · 5 investors · Other Health CareRule 506(b)
▶$1.2MraisedJun 2024 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John CerminaroExecutive Officer
- Marvin WoodallDirector
- Kelly ElliottDirector
- Todd RichmondDirector
- Michael J. CerminaroExecutive Officer, Director
- Tony LitwillerExecutive Officer
- Paul A. StewartDirector
- Offering amount
- $5M
- Amount sold
- $1.2M
- Minimum investment
- $50K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedMay 2024 · 56 investors · Other Health CareRule 506(b)
▶$4.8MraisedMay 2024 · 56 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tony LitwillerExecutive Officer
- Paul A. StewartDirector
- Marvin WoodallDirector
- Kelly ElliottDirector
- John CerminaroExecutive Officer
- Michael J. CerminaroExecutive Officer, Director
- Todd RichmondDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedAug 2022 · 50 investors · Other Health CareRule 506(b)
▶$2MraisedAug 2022 · 50 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marvin WoodallExecutive Officer, Director
- Paul A. StewartDirector
- Michael J. CerminaroExecutive Officer, Director
- John CerminaroExecutive Officer
- Todd RichmondDirector
- Brian G. FirthExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedNov 2021 · 46 investors · Other Health CareRule 506(b)
▶$5MraisedNov 2021 · 46 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. StewartDirector
- Michael J. CerminaroExecutive Officer, Director
- Brian G. FirthExecutive Officer, Director
- Todd RichmondDirector
- John CerminaroExecutive Officer
- Marvin WoodallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$9.8MraisedFeb 2020 · 33 investors · Other Health CareRule 506(b)
▶$9.8MraisedFeb 2020 · 33 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marvin WoodallExecutive Officer, Director, Promoter
- Michael J. CerminaroExecutive Officer, Director, Promoter
- Brian G. FirthExecutive Officer, Director
- Paul A. StewartDirector
- Todd RichmondDirector
- John CerminaroExecutive Officer
- Amount sold
- $9.8M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Inari Medical Inc.Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis. Its product portfolio includes the FlowTriever and ClotTriever systems, catheters, and blood return systems used by clinicians treating vascular blood clots.
Companies working in the same space as Thrombolex.
In the news
Frequently asked questions
- What does Thrombolex do?
- Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.
- Who founded Thrombolex?
- Thrombolex was founded by Riyaz Bashir in 2016.
- Who are Thrombolex's investors?
- Thrombolex's investors include Delaware Crossing Investor Group, OrbiMed.
- How much funding has Thrombolex raised?
- Thrombolex has disclosed $55.6M raised across 6 of its 7 known rounds.
- Where is Thrombolex headquartered?
- Thrombolex is headquartered in Kingston, US.